MCL Literature Feed

This preclinical study identifies the CERS6-AS1/FGFR1 axis as a synthetic vulnerability, offering a novel therapeutic strategy to disrupt stromal cell-mediated proliferation and overcome resistance in MCL.

Hyperleukocytosis from undiagnosed leukemic MCL interfered with an HbA1c test, revealing a novel diagnostic pathway where a common diabetes lab test can signal an underlying hematologic malignancy.

Preclinically, dual inhibition of Hedgehog/GLI1 and Wnt/β-catenin pathways synergistically suppresses MCL cells and enhances sensitivity to chemotherapy and ibrutinib, suggesting a new approach to overcome resistance.

This first-reported case of sphenoid sinus MCL causing acute bilateral blindness demonstrates that prompt chemo-surgical intervention can partially reverse vision loss, highlighting a rare but critical CNS presentation.

This review synthesizes current and emerging therapies for relapsed/refractory MCL, including BTKi, BCL2i, CAR-T, and bispecifics, emphasizing the evolving challenge of post-BTKi treatment sequencing.

In younger, BTKi-naïve MCL patients with late relapse (>24 months), second-line BTKi significantly improved PFS and OS versus chemoimmunotherapy, establishing it as the preferred approach in this setting.

Spatial multiomics reveals CD163+ macrophages activate the MAPK prosurvival pathway in MCL cells, identifying MAPK inhibitors as a potential therapy for patients with high macrophage infiltration.

A rare case of mantle cell lymphoma discovered incidentally within a benign Warthin tumor highlights a diagnostic pitfall, underscoring the need to pathologically evaluate lymphoid stroma to avoid missed diagnoses.

Seven-year follow-up of venetoclax-ibrutinib in relapsed/refractory MCL shows durable responses (30% PFS) and demonstrates feasibility of MRD-guided treatment-free remission, supporting a long-term chemotherapy-free strategy.

This case of atypical plasma cell leukemia, initially misdiagnosed as blastoid mantle cell lymphoma, highlights the critical diagnostic challenge of distinguishing between aggressive, morphologically similar hematologic malignancies.

A survey of US and European hematologists reveals significant knowledge gaps in MCL guidelines, molecular testing, and toxicity management, highlighting a need for improved continuing medical education.

Preclinical models show the PI3K inhibitor idelalisib synergizes with the CDK4/6 inhibitor palbociclib, providing a rationale for a novel combination therapy in relapsed/refractory MCL.

This case report documents a rare presentation of mantle cell lymphoma as complete heart block from cardiac metastasis, highlighting a critical differential diagnosis for unexplained conduction abnormalities.

This case report describes the rare simultaneous occurrence of recurrent hepatocellular carcinoma and mantle cell lymphoma, highlighting the diagnostic and therapeutic challenges of managing co-existing malignancies.

Preclinical data shows the novel CTPS1 inhibitor STP-B has single-agent activity in high-risk MCL (blastoid, TP53-mutated) and synergizes with venetoclax by downregulating MCL1, offering a new combination strategy.

This large, real-world French database study on ibrutinib focuses exclusively on patients with CLL, providing no specific data or insights relevant to mantle cell lymphoma.

This case report details an extremely rare presentation of relapsed mantle cell lymphoma as an appendiceal volvulus, highlighting an unusual cause of acute abdominal pain requiring emergent surgery.

This case report describes the rare but life-threatening development of disseminated intravascular coagulation (DIC) in a patient with the typically indolent, asymptomatic leukemic non-nodal variant of MCL.

A high monocyte-to-platelet ratio (MPR ≥ 3) at diagnosis is a novel, independent prognostic biomarker for inferior progression-free survival in transplant-ineligible mantle cell lymphoma patients.

This review summarizes the evolving treatment landscape for relapsed/refractory MCL, highlighting survival gains from BTKi and CAR-T and outlining emerging therapies like bispecifics for multiply-refractory patients.

This large, real-world study confirms cytarabine-based induction provides the longest front-line PFS (68 months), while second-line chemotherapy outcomes are poor (14 months PFS), highlighting the need for novel agents.

This study identifies a rare CD5/SOX11 double-negative pleomorphic MCL, showing CCND1 rearrangement is the key feature to differentiate it from cyclin D1-positive DLBCL, ensuring correct diagnosis.

A rare case of MCL presenting as diffuse polyposis throughout the entire GI tract achieved complete response after R-CHOP followed by salvage chemotherapy plus ibrutinib, highlighting this unusual presentation.

This case report details the practical challenges and potential toxicities of administering CAR-T cell therapy to an elderly MCL patient with high tumor burden, informing management of this high-risk group.

This case report details a rare MCL presentation as intestinal intussusception, requiring surgical resection for diagnosis and initial management prior to systemic chemotherapy in a young patient.

This case report identifies life-threatening aplastic anemia as a rare but fatal toxicity of acalabrutinib in MCL, urging clinicians to consider it in patients developing pancytopenia.

This study analyzes molecular responses in exceptional responders to the BTKi tirabrutinib, aiming to identify biomarkers for deep, durable remissions in relapsed/refractory mantle cell lymphoma.

This paper outlines the diagnostic and treatment challenges of rare ocular and nasopharyngeal MCL, highlighting the necessity of a multidisciplinary approach for managing these extranodal presentations.

This review summarizes how molecular profiling (e.g., TP53) and MRD are reshaping MCL therapy by integrating novel agents into frontline care, personalizing treatment, and improving high-risk patient outcomes.

This meta-analysis of phase 2/3 trials quantifies venous thromboembolism risk after CAR-T therapy, providing crucial data to guide thromboprophylaxis strategies in MCL patients.